Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-D6-B483
- Development stage
- Unknown
- Lead developer
- Ashvattha Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-D6-B483 is a radiolabeled diabody (a non-covalent dimer of single-chain Fv fragments) derived from the human monoclonal antibody B483. It specifically targets Carbonic Anhydrase IX (CAIX), a cell-surface enzyme that is highly overexpressed in clear cell renal cell carcinoma (ccRCC) and other hypoxic tumors, while showing minimal expression in normal tissues. The diabody format (D6) is engineered for rapid blood clearance and high tumor penetration, which are advantageous for diagnostic imaging compared to full-length antibodies. Labeled with the gamma-emitting isotope Indium-111 (111In), it is utilized for Single Photon Emission Computed Tomography (SPECT) imaging to detect CAIX-positive lesions, assess tumor hypoxia, and potentially select patients for CAIX-targeted therapies.
- Other names
- 111In-labeled D6-B483 diabodyIndium-111 D6-B483Indium111 D6-B483Indium 111 D6-B483111In-D6-B483 diabody
02
Targets
TAM (TAM receptor tyrosine kinases)
Beyond the preview
Go deeper on 111In-D6-B483.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-D6-B483.